

# Market Announcement

10 March 2026

---

## Imugene Limited (ASX: IMU) – Trading Halt

Trading in the securities of Imugene Limited ('IMU') will be halted at the request of IMU, pending the release of an announcement by IMU.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Thursday, 12 March 2026; or
- the release of the announcement to the market.

IMU's request for a trading halt is attached below for the information of the market.

### Issued by

ASX Compliance



**IMUGENE**

Developing Cancer  
Immunotherapies

Imugene Limited  
ABN 99 009 179 551  
www.imugene.com

Suite 12.01, Level 12  
4-6 Bligh Street  
Sydney NSW 2000  
AUSTRALIA

10 March 2026

Ms Melissa Kostopoulous  
Compliance Adviser  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

**Via email:** [tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au)

Dear Melissa,

**TRADING HALT REQUEST – ASX: IMU**

In accordance with ASX Listing Rule 17.1, Imugene Limited (the Company) hereby requests that its securities be placed into an immediate trading halt. For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the Company is seeking a trading halt pending an announcement in relation to a proposed capital raising;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company releasing an announcement in relation to the capital raising or the opening of trading on Thursday, 12 March 2026;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

Darren Keamy  
Company Secretary

For personal use only